This is the first of a series on the question of data availability, structure, value and challenges.
The oft-told story is that it took Thomas Edison’s 10,000 attempts to perfect the invention of the light bulb. He is famously quoted as saying of his many prior unsuccessful efforts, “I have not failed. I’ve just found 10,000 ways that won’t work.”
There is an ongoing discussion as to whether the biopharma industry should adopt a similar attitude when it comes clinical trials. A recent article in BioCentury outlined the clinical trial tug-of-war between traditional frequentists and Bayesians who have been making their way into the arena, starting first in the medical devices field....
There's been a lot of conversation around value-based care (VBC) models, and payers, providers and biopharma – each have their own take on what VBC means to them. But lately there has been more conversation around patient-centered care and what that looks like through the lens of a value-based approach.
Value-based care – paying for outcomes as opposed to a fee for service or procedure – has been growing in recent years. A recent report found that the percentage of healthcare payments tied to value-based care reached 34 percent in 2017, up 23 percent from 2015, and affecting approximately 226...
